The novel inosine analogue INO-2002 exerts an anti-inflammatory effect in a murine model of acute lung injury

Shock

Volumn 32, Issue 3, 2009, Pages 258-262

  Mabley, Jon G ^a   Pacher, Pal ^b   Murthy, Kanneganti G K ^c   Williams, William ^c   Southan, Garry J ^c   Salzman, Andrew L ^c   Szabo, Csaba ^d  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c INOTEK CORPORATION   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Adenosine; Cytokines; Inflammation; Inosine; Lung; Purine

Indexed keywords

INO 2002; INOSINE DERIVATIVE; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; LEUKOCYTE MIGRATION; LUNG EDEMA; LUNG LAVAGE; MALE; MOUSE; NONHUMAN;

ACUTE LUNG INJURY; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOKINE CCL3; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; INOSINE; INTERLEUKIN-1; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LUNG; MALE; MICE; MICE, INBRED BALB C; PEROXIDASE; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 69549108327     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31819c3414     Document Type: Article

References (38)

1. Artigas A, Bernard GR, Carlet J, Dreyfuss D, Gattinoni L, Hudson L, Lamy M, Marini JJ, Matthay MA, Pinsky MR, et al.: The American-European Consensus Conference on ARDS, part 2. Ventilatory, pharmacologic, supportive therapy, study design strategies and issues related to recovery and remodeling. Intensive Care Med 24:378-398, 1998.
2. Abraham E, Carmody A, Shenkar R, Arcaroli J: Neutrophils as early immunologic effectors in hemorrhage- or endotoxemia-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol 279:L1137-L1145, 2000. (Pubitemid 32009500)
3. Chignard M, Balloy V: Neutrophil recruitment and increased permeability during acute lung injury induced by lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol 279:L1083-L1090, 2000. (Pubitemid 32009494)
4. Martin TR: Cytokines and the acute respiratory distress syndrome (ARDS): a question of balance. Nat Med 3:272-273, 1997. (Pubitemid 27112917)
5. Matthay MA, Geiser T, Matalon S, Ischiropoulos H: Oxidant-mediated lung injury in the acute respiratory distress syndrome. Crit Care Med 27:2028-2030, 1999. (Pubitemid 29455146)
6. Peng X, Abdulnour RE, Sammani S, Ma SF, Han EJ, Hasan EJ, Tuder R, Garcia JG, Hassoun PM: Inducible nitric oxide synthase contributes to ventilator-induced lung injury. Am J Respir Crit Care Med 172:470-479, 2005. (Pubitemid 41117393)
7. Borron P, McIntosh JC, Korfhagen TR, Whitsett JA, Taylor J, Wright JR: Surfactant-associated protein A inhibits LPS-induced cytokine and nitric oxide production in vivo. Am J Physiol Lung Cell Mol Physiol 278:L840-L847, 2000. (Pubitemid 30220046)
8. Harrod KS, Mounday AD, Whitsett JA: Adenoviral E3-14.7K protein in LPS-induced lung inflammation. Am J Physiol Lung Cell Mol Physiol 278:L631-L639, 2000.
9. Kabir K, Gelinas JP, Chen M, Chen D, Zhang D, Luo X, Yang JH, Carter D, Rabinovici R: Characterization of a murine model of endotoxin-induced acute lung injury. Shock 17:300-303, 2002.
10. Liaudet L, Mabley JG, Pacher P, Virag L, Soriano FG, Marton A, Hasko G, Deitch EA, Szabo C: Inosine exerts a broad range of antiinflammatory effects in a murine model of acute lung injury. Ann Surg 235:568-578, 2002. (Pubitemid 34258357)
11. Hasko G, Sitkovsky MV, Szabo C: Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci 25:152-157, 2004.
12. Hasko G, Kuhel DG, Nemeth ZH, Mabley JG, Stachlewitz RF, Virag L, Lohinai Z, Southan GJ, Salzman AL, Szabo C: Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J Immunol 164:1013-1019, 2000. (Pubitemid 30043729)
13. Marton A, Pacher P, Murthy KG, Nemeth ZH, Hasko G, Szabo C: Antiinflammatory effects of inosine in human monocytes, neutrophils and epithelial cells in vitro. Int J Mol Med 8:617-621, 2001.
14. Liaudet L, Mabley JG, Soriano FG, Pacher P, Marton A, Hasko G, Szabo C: Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture. Am J Respir Crit Care Med 164:1213-1220, 2001. (Pubitemid 33052253)
15. Garcia Soriano F, Liaudet L, Marton A, Hasko G, Batista Lorigados C, Deitch EA, Szabo C: Inosine improves gut permeability and vascular reactivity in endotoxic shock. Crit Care Med 29:703-708, 2001. (Pubitemid 32299705)
16. Mabley JG, Pacher P, Liaudet L, Soriano FG, Hasko G, Marton A, Szabo C, Salzman AL: Inosine reduces inflammation and improves survival in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 284:G138-G144, 2003. (Pubitemid 36076259)
17. Mabley JG, Rabinovitch A, Suarez-Pinzon W, Hasko G, Pacher P, Power R, Southan G, Salzman A, Szabo C: Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes. Mol Med 9:96-104, 2003. (Pubitemid 36819965)
18. Darlington DN, Gann DS: Inosine infusion prevents mortality in endotoxic shock. J Trauma 59:1432-1435; discussion 1435, 2005.
19. Szabo G, Stumpf N, Radovits T, Sonnenberg K, Gero D, Hagl S, Szabo C, Bahrle S: Effects of inosine on reperfusion injury after heart transplantation. Eur J Cardiothorac Surg 30:96-102, 2006. (Pubitemid 43850335)
20. Qiu FH, Wada K, Stahl GL, Serhan CN: IMP and AMP deaminase in reperfusion injury down-regulates neutrophil recruitment. Proc Natl Acad Sci U S A 97:4267-4272, 2000. (Pubitemid 30226122)
21. Mabley JG, Pacher P, Murthy KG, Williams W, Southan GJ, Salzman AL, Szabo C: The novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic mouse models of type I diabetes. J Endocrinol 198:581-589, 2008.
22. Liaudet L, Pacher P, Mabley JG, Virag L, Soriano FG, Hasko G, Szabo C: Activation of poly(ADP-ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Am J Respir Crit Care Med 165:372-377, 2002. (Pubitemid 34118511)
23. Liaudet L, Szabo C, Evgenov OV, Murthy KG, Pacher P, Virag L, Mabley JG, Marton A, Soriano FG, Kirov MY, et al.: Flagellin from Gram-negative bacteria is a potent mediator of acute pulmonary inflammation in sepsis. Shock 19:131-137, 2003.
24. Soriano FG, Liaudet L, Szabo E, Virag L, Mabley JG, Pacher P, Szabo C: Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1- deficient mice. Shock 17:286-292, 2002.
25. Abraham E, Arcaroli J, Shenkar R: Activation of extracellular signal-regulated kinases, NF-kappa B, and cyclic adenosine 5′- monophosphate response element-binding protein in lung neutrophils occurs by differing mechanisms after hemorrhage or endotoxemia. J Immunol 166:522-530, 2001. (Pubitemid 32038472)
26. Strieter RM, Kunkel SL, Keane MP, Standiford TJ: Chemokines in lung injury: Thomas A. Neff Lecture. Chest 116:103S-110S, 1999.
27. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A: Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 108:1303-1314, 1995.
28. Meduri GU, Headley S, Kohler G, Stentz F, Tolley E, Umberger R, Leeper K: Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 107:1062-1073, 1995.
29. Takala A, Jousela I, Takkunen O, Kautiainen H, Jansson SE, Orpana A, Karonen SL, Repo H: A prospective study of inflammation markers in patients at risk of indirect acute lung injury. Shock 17:252-257, 2002.
30. Ware LB: Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med 27:337-349, 2006. (Pubitemid 44272603)
31. Kollef MH, Schuster DP: The acute respiratory distress syndrome. N Engl J Med 332:27-37, 1995.
32. Gomez G, Sitkovsky MV: Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo. Blood 102:4472-4478, 2003. (Pubitemid 37494112)
33. Nemeth ZH, Bleich D, Csoka B, Pacher P, Mabley JG, Himer L, Vizi ES, Deitch EA, Szabo C, Cronstein BN, et al.: Adenosine receptor activation ameliorates type 1 diabetes. FASEB J 21:2379-2388, 2007. (Pubitemid 47230668)
34. Virag L, Szabo C: Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death. FASEB J 15:99-107, 2001. (Pubitemid 32061660)
35. Mabley JG, Jagtap P, Perretti M, Getting SJ, Salzman AL, Virag L, Szabo E, Soriano FG, Liaudet L, Abdelkarim GE, et al.: Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase. Inflamm Res 50:561-569, 2001. (Pubitemid 33121903)
36. Murakami K, Enkhbaatar P, Shimoda K, Cox RA, Burke AS, Hawkins HK, Traber LD, Schmalstieg FC, Salzman AL, Mabley JG, et al.: Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis. Shock 21:126-133, 2004.
37. Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87:315-424, 2007. (Pubitemid 46217686)
38. Becker BF, Reinholz N, Ozcelik T, Leipert B, Gerlach E: Uric acid as radical scavenger and antioxidant in the heart. Pflugers Arch 415:127-135, 1989. (Pubitemid 19275785)